Vancomycin-Resistant Enterococcus faecium Infections R&D Pipeline Analysis Report, Q4 2020
Vancomycin-Resistant Enterococcus faecium Infections Pipeline Overview
The Q4 Vancomycin-Resistant Enterococcus faecium Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Vancomycin-Resistant Enterococcus faecium Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Vancomycin-Resistant Enterococcus faecium Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Vancomycin-Resistant Enterococcus faecium Infections disease overview, Vancomycin-Resistant Enterococcus faecium Infections types, Vancomycin-Resistant Enterococcus faecium Infections symptoms, causes, and FDA/EMA approved treatment options.
Vancomycin-Resistant Enterococcus faecium Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Vancomycin-Resistant Enterococcus faecium Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Vancomycin-Resistant Enterococcus faecium Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 21 companies. Business profiles and contact details of the companies actively perusing Vancomycin-Resistant Enterococcus faecium Infections pipeline are assessed.
Vancomycin-Resistant Enterococcus faecium Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Vancomycin-Resistant Enterococcus faecium Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Vancomycin-Resistant Enterococcus faecium Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Vancomycin-Resistant Enterococcus faecium Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Vancomycin-Resistant Enterococcus faecium Infections Pipeline Market News and Developments during 2020
The Vancomycin-Resistant Enterococcus faecium Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Vancomycin-Resistant Enterococcus faecium Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Vancomycin-Resistant Enterococcus faecium Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Vancomycin-Resistant Enterococcus faecium Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Vancomycin-Resistant Enterococcus faecium Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Vancomycin-Resistant Enterococcus faecium Infections disease overview, Vancomycin-Resistant Enterococcus faecium Infections types, Vancomycin-Resistant Enterococcus faecium Infections symptoms, causes, and FDA/EMA approved treatment options.
Vancomycin-Resistant Enterococcus faecium Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Vancomycin-Resistant Enterococcus faecium Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Vancomycin-Resistant Enterococcus faecium Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 21 companies. Business profiles and contact details of the companies actively perusing Vancomycin-Resistant Enterococcus faecium Infections pipeline are assessed.
Vancomycin-Resistant Enterococcus faecium Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Vancomycin-Resistant Enterococcus faecium Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Vancomycin-Resistant Enterococcus faecium Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Vancomycin-Resistant Enterococcus faecium Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Vancomycin-Resistant Enterococcus faecium Infections Pipeline Market News and Developments during 2020
The Vancomycin-Resistant Enterococcus faecium Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Vancomycin-Resistant Enterococcus faecium Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Vancomycin-Resistant Enterococcus faecium Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 21 companies are included including Acurx Pharmaceuticals llc, Aphios Corp, Arietis Corp, Armata Pharmaceuticals Inc, Curza Global LLC, Daiichi Sankyo Co Ltd, Helix BioMedix Inc, Hsiri Therapeutics LLC, Karveel Pharmaceuticals, MGB Biopharma Ltd, MicuRx Pharmaceuticals Inc, Naicons Srl, NovoBiotic Pharmaceuticals LLC, Opal Biosciences Ltd, Oragenics Inc, Ovensa Inc, QureTech Bio AB, Rebiotix Inc, Sealife PHARMA GMBH, Sentinella Pharmaceuticals Inc, Wockhardt Ltd,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Vancomycin-Resistant Enterococcus faecium Infections pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Vancomycin-Resistant Enterococcus faecium Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Vancomycin-Resistant Enterococcus faecium Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Vancomycin-Resistant Enterococcus faecium Infections pipeline
2.5 Active Companies Developing Vancomycin-Resistant Enterococcus faecium Infections pipeline
3. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acurx Pharmaceuticals llc
Aphios Corp
Arietis Corp
Armata Pharmaceuticals Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Helix BioMedix Inc
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
QureTech Bio AB
Rebiotix Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd
5. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Vancomycin-Resistant Enterococcus faecium Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Vancomycin-Resistant Enterococcus faecium Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Vancomycin-Resistant Enterococcus faecium Infections pipeline
2.5 Active Companies Developing Vancomycin-Resistant Enterococcus faecium Infections pipeline
3. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acurx Pharmaceuticals llc
Aphios Corp
Arietis Corp
Armata Pharmaceuticals Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Helix BioMedix Inc
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
QureTech Bio AB
Rebiotix Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd
5. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
